Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)
Eric F. Morand(Novartis (Switzerland)), Thomas Dörner(German Rheumatism Research Centre), Edward M Vital(University of Leeds), Inmaculada de la Torre(Eli Lilly (United States)), Bochao Jia(Eli Lilly (United States)), Daniel J. Wallace(Cedars-Sinai Medical Center), Richard Furie(Hofstra University), Michelle Petri(Johns Hopkins University), Gabriella Meszaros(Eli Lilly (United States)), Brenda Crowe(Eli Lilly (United States)), Maria Silk(Eli Lilly (United States)), Ronald van Vollenhoven(Amsterdam University Medical Centers), Christina Dickson(Eli Lilly (United States)), Marta Mosca(University of Pisa)
Cited by 151
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
|New England Journal of Medicine|2005|1.1k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
The immune cell landscape in kidneys of patients with lupus nephritis
|Nature Immunology|2019|840
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
|Annals of the Rheumatic Diseases|2015|728